Drooid Logo
Back to story perspectives

Full Breakdown

Legal Battle Over $7.25 B Roundup Settlement Intensifies as Supreme Court Case Looms

5/23/2026, 3:14:45 AM

Proposed $7.25 B Settlement Under Legal Challenge

A $7.25 billion settlement filed in St. Louis aims to resolve thousands of Roundup cancer claims. Plaintiffs must opt out by June 4. On May 22, attorney Ashley Keller moved to shift the case to federal court, arguing the state process was rushed. Bayer and claimants’ representatives call the filing a baseless delay tactic and argue the case should stay in Missouri.

Background and Key Actors

Bayer acquired Monsanto in 2018, inheriting Roundup. Bayer says it complied with federal pesticide labeling that does not require a cancer warning. The EPA finds Roundup not likely carcinogenic when used as directed; the IARC classified glyphosate probably carcinogenic in 2015. Bayer AG, Monsanto, plaintiff John Durnell (outside the settlement), attorney Ashley Keller, claimants’ representative Christopher Seeger, and the U.S. Supreme Court.

Timeline of Legal Moves

Settlement Terms and Payouts

The agreement requires Bayer to fund a special account for up to 21 years, with total contributions capped at $7.25 billion. Payments depend on exposure, age at diagnosis, and disease severity. An agricultural or industrial worker diagnosed before age 60 could receive an average $165,000; a claimant aged 78 or older would average $10,000.

Stakes and Impact

If many claimants opt out, Bayer can cancel the settlement, leaving thousands of lawsuits pending. The deal provides guaranteed compensation while shielding Bayer from further liability, a goal reinforced by its push for legislative protection. The outcome will shape future pesticide litigation and corporate liability strategies.

Official Statements

Bayer argued the proposed federal transfer lacks justification and that the case should remain in Missouri, emphasizing compliance with federal labeling standards. The EPA reiterated that Roundup does not require a cancer warning under current regulations. Plaintiffs cite the IARC’s 2015 “probably carcinogenic” classification as a basis for liability.

Criticism and Opposition

Plaintiffs’ counsel described the settlement as a “sweetheart deal” that provides insufficient compensation while giving Bayer broad protection. Keller said the June 4 deadline was crafted to maximize uncertainty about the Supreme Court’s ruling, pressuring claimants toward acceptance. Seeger characterized the move to federal court as an unjustified delay tactic.

Conflicting Reports

Regulatory views diverge: the EPA finds Roundup not likely carcinogenic when used as directed; the IARC classified glyphosate probably carcinogenic in 2015. The Supreme Court’s position on liability remains undisclosed, and the number of potential opt-outs is unknown.

Verbatim Quotes

  • “This is a huge settlement that is extinguishing the rights of tens of thousands of cancer victims,” — Ashley Keller, Attorney for plaintiffs
  • “It was rushed into state court.” — Ashley Keller, Attorney for plaintiffs
  • “a baseless delay tactic that should be promptly declined.” — Christopher Seeger, Claimants’ representative

What’s Next

Supreme Court decision expected by early July; July 9 hearing will decide settlement’s fate.